DE69609739D1 - Pertussistoxin enthaltender Influenzaimpfstoff - Google Patents

Pertussistoxin enthaltender Influenzaimpfstoff

Info

Publication number
DE69609739D1
DE69609739D1 DE69609739T DE69609739T DE69609739D1 DE 69609739 D1 DE69609739 D1 DE 69609739D1 DE 69609739 T DE69609739 T DE 69609739T DE 69609739 T DE69609739 T DE 69609739T DE 69609739 D1 DE69609739 D1 DE 69609739D1
Authority
DE
Germany
Prior art keywords
amino acid
pertussis toxin
influenza vaccine
vaccine containing
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69609739T
Other languages
English (en)
Other versions
DE69609739T2 (de
Inventor
Mark Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltech Pharma Europe Ltd
Original Assignee
Medeva Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69609739(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medeva Europe Ltd filed Critical Medeva Europe Ltd
Application granted granted Critical
Publication of DE69609739D1 publication Critical patent/DE69609739D1/de
Publication of DE69609739T2 publication Critical patent/DE69609739T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE69609739T 1995-01-16 1996-01-09 Pertussistoxin enthaltender Influenzaimpfstoff Expired - Fee Related DE69609739T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9500788.6A GB9500788D0 (en) 1995-01-16 1995-01-16 Vaccine compositions

Publications (2)

Publication Number Publication Date
DE69609739D1 true DE69609739D1 (de) 2000-09-21
DE69609739T2 DE69609739T2 (de) 2001-04-12

Family

ID=10768080

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69609739T Expired - Fee Related DE69609739T2 (de) 1995-01-16 1996-01-09 Pertussistoxin enthaltender Influenzaimpfstoff

Country Status (8)

Country Link
EP (1) EP0721782B1 (de)
AT (1) ATE195427T1 (de)
DE (1) DE69609739T2 (de)
DK (1) DK0721782T3 (de)
ES (1) ES2150631T3 (de)
GB (1) GB9500788D0 (de)
GR (1) GR3034773T3 (de)
PT (1) PT721782E (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2179744B1 (de) 2004-09-09 2010-12-01 Novartis Vaccines and Diagnostics GmbH Verminderung von potentiellen iatrogenen Risiken in Verbindung mit Influenza Impfstoffen
JP2008519042A (ja) 2004-11-03 2008-06-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド インフルエンザワクチン接種
TW201103980A (en) * 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
AU2011300402B2 (en) 2010-09-07 2015-01-22 Novartis Ag Generic assays for detection of mammalian reovirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03135923A (ja) * 1989-10-20 1991-06-10 Chemo Sero Therapeut Res Inst 百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants

Also Published As

Publication number Publication date
ES2150631T3 (es) 2000-12-01
DE69609739T2 (de) 2001-04-12
GB9500788D0 (en) 1995-03-08
GR3034773T3 (en) 2001-02-28
DK0721782T3 (da) 2000-12-18
PT721782E (pt) 2001-02-28
ATE195427T1 (de) 2000-09-15
EP0721782B1 (de) 2000-08-16
EP0721782A3 (de) 1997-04-16
EP0721782A2 (de) 1996-07-17

Similar Documents

Publication Publication Date Title
MX9803290A (es) Composiciones de la vacuna influenza.
AU3526995A (en) Vaccine compositions
FI974423A (fi) Immunologiset yhdistelmäkoostumukset ja menetelmät
FI913820A (fi) Traodlikt hemagglutinin fraon bordetella pertussis som baerarmolekyl foer konjugatvaccin.
DE69326948D1 (de) Impfstoffzusammensetzungen fuer mukosale abgabe
ES2074950A1 (es) Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
DK0425082T3 (da) Vacciner
DK0725653T3 (da) Vaccinepræparater
DE69609739D1 (de) Pertussistoxin enthaltender Influenzaimpfstoff
FR2693655B1 (fr) Vaccin antirabique avirulent.
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
BR0013574A (pt) Antìgeno vacina de moraxella
ES2058570T3 (es) Procedimiento para la obtencion de una vacuna antirrabica no virulenta.
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8339 Ceased/non-payment of the annual fee